Yelin Lapidot Holdings Management Ltd. lessened its stake in Perrigo Company plc (NYSE:PRGO – Free Report) by 36.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 170,000 shares of the company’s stock after selling 96,539 shares during the period. Yelin Lapidot Holdings Management Ltd. owned 0.12% of Perrigo worth $1,826,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also made changes to their positions in the company. EverSource Wealth Advisors LLC grew its stake in Perrigo by 116.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock worth $26,000 after buying an additional 1,014 shares during the last quarter. Geneos Wealth Management Inc. lifted its stake in Perrigo by 439.1% in the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after buying an additional 786 shares during the last quarter. UMB Bank n.a. lifted its stake in Perrigo by 161.5% in the fourth quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after buying an additional 1,213 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Perrigo in the fourth quarter valued at approximately $28,000. Finally, CWM LLC grew its position in shares of Perrigo by 230.0% during the fourth quarter. CWM LLC now owns 2,191 shares of the company’s stock worth $31,000 after acquiring an additional 1,527 shares during the last quarter. 95.91% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
PRGO has been the subject of several research reports. Weiss Ratings upgraded shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $19.33.
Perrigo Stock Down 0.3%
PRGO stock opened at $9.93 on Monday. The stock has a market capitalization of $1.37 billion, a PE ratio of -0.76, a price-to-earnings-growth ratio of 1.18 and a beta of 0.51. The company has a fifty day moving average of $11.01 and a 200-day moving average of $12.21. The company has a debt-to-equity ratio of 1.45, a quick ratio of 1.59 and a current ratio of 2.72. Perrigo Company plc has a one year low of $9.23 and a one year high of $28.43.
Perrigo (NYSE:PRGO – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. The firm had revenue of $841.80 million during the quarter, compared to analysts’ expectations of $1.04 billion. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The firm’s revenue for the quarter was down 7.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.60 earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, analysts expect that Perrigo Company plc will post 2.11 EPS for the current year.
Perrigo Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th were paid a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a dividend yield of 11.7%. The ex-dividend date of this dividend was Friday, May 29th. Perrigo’s dividend payout ratio is -8.85%.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.
Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.
Featured Articles
- Five stocks we like better than Perrigo
- As Stablecoins Keep Growing, These 2 Stocks Benefit
- Apple Just Handed These 4 Memory Stocks Their Best News of the Year
- Costco’s Secret Growth Engine May Be Running Out of Gas
- Why Alphabet’s Pullback May Be an Opportunity in Disguise
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.
